Matteo, Author at Golgi Neurosciences

Golgi Neurosciences celebrates Lario Therapeutics being awarded “Company Making a Difference 2023 Preclinical” by the Loulou Foundation

14 November 20239 November 2023 by Matteo

Lario Therapeutics Limited, a biopharmaceutical company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders.

Golgi Neurosciences announces Acousia Therapeutics receiving the approval for Phase 2 clinical trials

14 November 202310 October 2023 by Matteo

Acousia Therapeutics GmbH, a clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss.

Golgi Neurosciences, a unique incubator to combat neurodegenerative disorders, starts operating

14 November 20235 July 2023 by Matteo

Golgi Neurosciences Srl is proud to announce its launch as an independent and unique incubator. The company is dedicated to the discovery and development of innovative small molecule treatments to combat neurodegenerative diseases.